<h4>Background</h4>Currently, there is no consensus on the optimal treatment sequence for NSCLC patients with class II-III <i>BRAF</i> mutations, where standard of care implies immunochemotherapy and scarce data on targeted therapy is available.<h4>Materials and methods</h4>This is an observational, single centre case series of 9 patients collected in a Cancer Institute in Italy diagnosed with NSCLC with a <i>BRAF</i> class II or III mutation between 2020 and April 2025. This evidence concerns the gene BRAF and non-small cell lung carcinoma.